Encoded Therapeutics

Encoded Therapeutics

  • Founded: 2015
  • Location: South SF, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: Dravet syndrome (ODD)
  • Drug types: NEU, GEN, PED
  • Lead product: ETX101
  • Product link: https://encoded.com/programs/etx101-for-dravet-syndrome/
  • Funding: $135M D Jul 2020; $104M C Jun 2019; $54M prior to Jun 2019


encoded.com

linkedin.com

job board


Short description:

Gene Therapy

Drug notes:

Undisclosed programs RD pediatric CNS disorders

Long description:

Encoded Therapeutics is creating next-generation molecular therapies that leverage the regulatory regions of DNA. Encoded’s name derives from the epigenetic code that influences when genes are expressed within a cell. Using genomics-driven screening and machine learning algorithms, Encoded is identifying and optimizing synthetic human regulatory elements to modulate the function of diseased cells by changing gene expression. Their current platform utilizes AAV vectors so that they can deliver the human regulatory elements specifically to disease-relevant cell types. Encoded’s precision gene therapies therefore have the potential to target specific cell types to address a variety of disease mechanisms. Currently, Encoded is focusing on pediatric central nervous system disorders.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com